The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia

被引：0
|
作者：
Al-Sawaf, Othman [1 ,2 ,3 ,4 ,5 ]
Hallek, Michael [1 ,2 ,3 ]
Fischer, Kirsten [1 ,2 ,3 ]
机构：
[1] Univ Cologne, Fac Med, Cologne, Germany
[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[3] Ctr Integrated Oncol Aachen Bonn Cologne Dusseldo, German CLL Study Grp, Aachen, Germany
[4] Francis Crick Inst, London, England
[5] UCL, UCL Canc Inst, London, England
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2022年 / 20卷 / 02期
关键词：
Chemoimmunotherapy; chronic lymphocytic leukemia (CLL); fixed-duration therapy; minimal residual disease (MRD); targeted agents; OPEN-LABEL; FLOW-CYTOMETRY; FOLLOW-UP; INDEPENDENT PREDICTOR; CELL TRANSPLANTATION; CLL; RITUXIMAB; VENETOCLAX; FLUDARABINE; CHEMOIMMUNOTHERAPY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Minimal residual disease (MRD) has evolved as a sensitive and highly prognostic surrogate parameter of response to therapy in chronic lymphocytic leukemia (CLL). Multiple methods have been established to measure and quantify MRD during and after therapy. The improved sensitivity of MRD measurements has made it possible to develop limited-duration therapies, first with chemotherapy and chemoimmunotherapy and now also with combined targeted therapy. Moreover, concepts to integrate MRD information beyond prognostication-to guide duration of treatment and determine sensitivity-are at present being explored in prospective trials. In this review, we summarize currently available methods of MRD detection, provide recent MRD data and outcomes from clinical trials in CLL, and discuss open questions and future approaches for MRD within and outside clinical trials.
引用
收藏
页码：97 / 103
页数：7
相关论文
共 50 条
  • [1] Assessing minimal residual disease in chronic lymphocytic leukemia
    Rawstron A.C.
    Hillmen P.
    Current Hematologic Malignancy Reports, 2008, 3 (1) : 47 - 53
  • [2] Eradication of minimal residual disease in chronic lymphocytic leukemia
    Schweighofer C.D.
    Hallek M.
    Wendtner C.-M.
    Current Hematologic Malignancy Reports, 2008, 3 (1) : 54 - 60
  • [3] Minimal residual disease assessment in chronic lymphocytic leukemia
    Maloum, Karim
    HEMATOLOGIE, 2006, 12 (04): : 274 - 281
  • [4] Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
    Del Giudice, Ilaria
    Raponi, Sara
    Della Starza, Irene
    De Propris, Maria Stefania
    Cavalli, Marzia
    De Novi, Lucia Anna
    Cappelli, Luca Vincenzo
    Ilari, Caterina
    Cafforio, Luciana
    Guarini, Anna
    Foa, Robin
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [5] The Detection of Minimal Residual Disease Status in Chronic Lymphocytic Leukemia
    Marti, Gerald E.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2011, 80B (06) : 344 - 345
  • [6] Beyond detectable minimal residual disease in chronic lymphocytic leukemia
    Hillmen, Peter
    SEMINARS IN ONCOLOGY, 2006, 33 (02) : S23 - S28
  • [7] Minimal residual disease monitoring in chronic lymphocytic leukemia.
    Mattei, D
    Lo Nigro, C
    Mordini, N
    Castellino, C
    Gallamini, A
    BLOOD, 2001, 98 (11) : 284B - 285B
  • [8] Minimal residual disease assessment in chronic lymphocytic leukemia.
    Maloum, K
    Magnac, C
    Sutton, L
    Leblond, V
    Cazin, B
    Boccaccio, C
    Davi, F
    Binet, JL
    MerleBeral, H
    Dighiero, G
    BLOOD, 1996, 88 (10) : 297 - 297
  • [9] IMPLEMENTATION OF MINIMAL RESIDUAL DISEASE IN CHRONIC LYMPHOCYTIC LEUKEMIA ON REUNION ISLAND
    Kittler, I.
    Letestu, R.
    Zunic, P.
    Clabe, A.
    HAEMATOLOGICA, 2015, 100 : 677 - 677
  • [10] Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL)
    Magnac, C
    Sutton, L
    Cazin, B
    Laurent, C
    Binet, JL
    Merle-Béral, H
    Dighiero, G
    Maloum, K
    HEMATOLOGY AND CELL THERAPY, 1999, 41 (01) : 13 - 18
12345